Cancer
- Cancer PHGKB -
What's New
Last Posted: Sep 14, 2019
- Why Aren’t Cancer Drugs Better? The Targets Might Be Wrong
C Zimmer, NY Times, September 13, 2019 - Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
DJ Pinato et al, JAMA Oncology, September 12, 2019 - Many cancer drugs aim at the wrong molecular targets- Analysis using CRISPR gene-editing technology suggests that drugs’ mechanism of action are misunderstood.
H Ledford, Nature, September 12, 2019 - ‘Precision nutrition’ may be on the horizon, but large-scale, definitive trials lacking
LL Peterson, Healio, Sepetmber 10, 2019 - HER2 and Breast Cancer - A Phenomenal Success Story.
Hayes Daniel F et al. The New England journal of medicine 2019 Sep - How Immunotherapy Might Be Used to Treat Heart Failure- Modified immune cells may be trained not just to attack cancer, but any cells in the body that cause disease
G Kolata, NY Times, September 11, 2019 - Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade.
Georgiadis Andrew et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep - Family Members at Higher Risk for Blood Cancers
P Harrison, Medscape, September 9, 2019 - Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.
Parikh Aparna R et al. Nature medicine 2019 Sep (9) 1415-1421 - Men, It’s Time for Real Talk about Prostate Health
DM Parker, CDC Blog, August 2019 - Clinical lessons learned from the first leg of the CAR T cell journey
RJ Majzner et al, Nature Medicine, September 10, 2019 - Genetic testing for BRCA: Which NCCN criteria tell the tale?
B Kronemyer, Contemporary Ob/Gyn, September 9, 2019 - Opportunities in Cancer Research: The Immune System and Microbiome
NCI 2021 annual plan, 2019 - Predicting pancreatic cancer survival via the tumor microbiome
H Stover, Nature Medicine, Sepetmber 9, 2019 - Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma.
Braun David A et al. JAMA oncology 2019 Sep
.png)
No hay comentarios:
Publicar un comentario